Entries by admin

QR Pharma Receives Seed Investment from Ben Franklin Technology Partners for Further Development of Clinical Stage Compounds to Treat Alzheimer’s Disease

Radnor, PA, April 6, 2009 QR Pharma, Inc., a newly formed specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, received a $500,000 investment from Ben Franklin Technology Partners of Southeastern PA. The investment will further the clinical development of two lines of compounds, Posiphen® and bisnorcymserine and their respective […]

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease

West Chester, PA, December 1, 2008 QR Pharma, Inc., a newly formed specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease (AD), today announced that QR has entered into a worldwide exclusive license with Torrey Pines Therapeutics, Inc. for three lines of compounds to treat cognitive impairment and Alzheimer’s disease […]

TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma

LA JOLLA, CA, November 18, 2008 – TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has licensed to QR Pharma, Inc. the worldwide rights to phenserine, Posiphen® and bisnorcymcerine. QR Pharma is an emerging biotechnology company focusing on the development of compounds to treat Alzheimer’s disease and other cognitive disorders. “We are pleased to […]